BioSniper
Phase 3 Readout~month

Phase 3 Topline: Explore the Relationship Between Single Nucleotide Polymorphisms and Abiraterone Response and Toxici

May 28, 2026
Company
Design Therapeutics, Inc. (DSGN)
Indication
Prostate Cancer

Other upcoming events for DSGN

Phase 3 ReadoutPhase 3 Topline: Explore the Relationship Between Single Nucleotide Polymorphisms and Topotecan Response and Toxicity
Oct 28, 2026
Phase 3 ReadoutPhase 3 Topline: Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Nov 28, 2026
Phase 3 ReadoutPhase 3 Topline: Explore the Relationship Between Single Nucleotide Polymorphisms and Etoposide Response and Toxicity
Dec 28, 2026
Phase 3 ReadoutPhase 3 Topline: Explore the Relationship Between Single Nucleotide Polymorphisms and Raloxifene Response and Toxicit
Dec 28, 2026
Phase 3 ReadoutPhase 3 Topline: Explore the Relationship Between Single Nucleotide Polymorphisms and Alectinib Response and Toxicity
Dec 28, 2026

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
DSGN OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About
  • Data Methodology

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle